. 2021 Jul 29;11(7):e048719. doi: 10.1136/bmjopen-2021-048719

Table 1.

Clinical characteristics of patients in included studies

Characteristics aspirin vs no	Kim¹²	Ishii¹⁴	Lim¹³	Lee¹¹	Cho¹⁵	Mori¹⁶
Age (year)	/	66.0±9.5 vs 67.0±8.4, p=0.428	49.0–62.0 vs 49.0–62.5, p=0.61	51.3±6.7 vs. 50.8±7.5, p=0.70	57.2±11.2 vs 53.5±11.3, p=0.001	65.4±9.9 vs 66.7±10.3, p=0.07
Males, n (%)	/	47 (42.0) vs 47 (42.0), p=1.000	359 (82.7) vs 243 (84.7), p=0.49	60 (78) vs 55 (71), p=0.354	412 (64.3) vs 590 (58.4), p=0.055	247 (73.7%) vs 253 (75.5%), p=0.66
Hypertension, n (%)	/	52 (46.4) vs 57 (50.9), p=0.504	156 (36.0) vs 104 (36.2), p=0.96	22 (29) vs 20 (26), p=0.717	294 (45.9) vs 320 (31.7), p=0.001	158 (47.2%) vs 166 (49.6%), p=0.59
Diabetes mellitus, n (%)	/	26 (23.2) vs 27 (24.1), p=0.875	98 (22.6) vs 66 (23.0), p=0.91	17 (22) vs 16 (19), p=0.547	73 (11.4) vs 83 (8.2), p=0.037	56 (16.7%) vs 56 (16.7%), p=1.00
Smoking, n (%)	/	59 (52.7) vs 52 (46.4), p=0.350	127 (29.3) vs 87 (30.3), p=0.78	55 (71) vs 57 (74), p=0.717	183 (28.9) vs 250 (24.7), p=0.005	202 (60.3%) vs 202 (60.3%), p=1.00
Dyslipidaemia, n (%)	/	62 (55.4) vs 60 (53.6), p=0.788	91 (21.0) vs 62 (21.6), p=0.84	/	98 (15.4) vs160 (15.8), p=0.800	156 (46.6%) vs 142 (42.4%), p=0.31
Ca channel blocker, n (%)	/	104 (92.9) vs 101 (90.2), p=0.472	420 (96.9) vs 275 (95.8), p=0.46	50 (65) vs 48 (62), p=0.738	152 (24.2) vs 162 (16.12), p=0.001	316 (94.3%) vs 313 (93.4%), p=0.75
Statin, n (%)	/	38 (33.9) vs 40 (35.7), p=0.779	182 (42.0) vs 113 (39.4), p=0.49	/	123 (19.7) vs 119 (11.9), p=0.001	103 (30.7%) vs 95 (28.4%), p=0.55
ACEI/ARB, n (%)	/	33 (29.5) vs 25 (22.3), p=0.288	69 (15.9) vs 43 (15.0), p=0.74	/	152 (24.3) vs 126 (12.6), p=0.001	73 (21.8%) vs 71 (21.2%), p=0.93
Beta-blocker, n (%)	/	6 (5.4) vs 7 (6.3), p=0.775	1 (0.2) vs 0 (0.0), p=0.48	17 (22) vs 23 (30), p=0.270	54 (8.65) vs 59 (5.88), p=0.065	/

ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker.